• linkedin
  • Increase Font
  • Sharebar

    Dr. Holden joins UCLA urology faculty

    Stuart Holden, MD, has joined the UCLA faculty as a health sciences clinical professor in urology at the David Geffen School of Medicine. He was also appointed associate director of the UCLA Institute of Urologic Oncology, according to a UCLA press release.

    Due to his expertise in treating urologic cancer, Dr. Holden will be working with Arie Belldegrun, MD, of UCLA, and will establish an executive urology program at the institution.

    “We are thrilled to have recruited Dr. Holden to join UCLA Urology. It is an honor to have Dr. Holden fortify our team with his extensive urologic oncology expertise as we continue to improve urologic health care and work to heal humankind, one patient at a time,” said Mark S. Litwin, MD, of UCLA, in the press release.

    Dr. Holden is joining UCLA from Cedars-Sinai Medical Center, Los Angeles, where he served as director of the Louis Warschaw Prostate Cancer Center and was the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. He has also held the position of medical director of the Prostate Cancer Foundation since its inception in 1993.

    Like this article? Check out these other recent Urology Times articles:

    Dr. Cheng named division head at Lurie Children's

    Dr. Schoenberg named chair at Albert Einstein

    Urology Times welcomes Dr. Rosevear as board member


    To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
     

    Benjamin P. Saylor
    Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll